Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years.
Patruno C, Fabbrocini G, Lauletta G, Boccaletti V, Colonna C, Cavalli R, Neri I, Ortoncelli M, Schena D, Stingeni L, Hansel K, Piccolo V, Di Brizzi V, Potenza C, Tolino E, Bianchi L, Manti S, De Pasquale R, Di Lernia V, Caminiti L, Galli E, Coppo P, Chiricozzi A, De Simone C, Guerriero C, Amoruso FG, Provenzano E, Leonardi S, Licari A, Marseglia GL, Palermo A, Di Pillo S, Russo D, Moschese V, Patella V, Peduto T, Ferreli C, Zangari P, Veronese F, Berti SF, Gruber M, Pezzolo E, Termine S, Satta R, Dragoni F, Esposito M, Fargnoli MC, Chiodini P, Vallone Y, di Vico F, Picone V, Napolitano M. Patruno C, et al. Among authors: amoruso fg. J Dermatolog Treat. 2023 Dec;34(1):2246602. doi: 10.1080/09546634.2023.2246602. J Dermatolog Treat. 2023. PMID: 37580895 Free article.
Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis).
Malagoli P, Dapavo P, Pavia G, Amoruso F, Argenziano G, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dini V, Girolomoni G, Guarneri C, Loconsole F, Narcisi A, Sampogna F, Travaglini M, Costanzo A. Malagoli P, et al. Dermatol Ther. 2022 Aug;35(8):e15608. doi: 10.1111/dth.15608. Epub 2022 Jun 8. Dermatol Ther. 2022. PMID: 35638250
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
Narcisi A, Valenti M, Gargiulo L, Ibba L, Amoruso F, Argenziano G, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Franchi C, Girolomoni G, Guarneri C, Loconsole F, Sampogna F, Travaglini M, Malagoli P, Costanzo A. Narcisi A, et al. J Eur Acad Dermatol Venereol. 2023 Jan;37(1):93-103. doi: 10.1111/jdv.18594. Epub 2022 Oct 5. J Eur Acad Dermatol Venereol. 2023. PMID: 36156312 Free PMC article.
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis).
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Fabbrocini G, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Sampogna F, Travaglini M, Costanzo A, Narcisi A. Gargiulo L, et al. Front Med (Lausanne). 2023 Jul 3;10:1196966. doi: 10.3389/fmed.2023.1196966. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37469659 Free PMC article.
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Sampogna F, Travaglini M, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. J Clin Med. 2024 Jan 16;13(2):495. doi: 10.3390/jcm13020495. J Clin Med. 2024. PMID: 38256629 Free PMC article.
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Fabbrocini G, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Sampogna F, Travaglini M, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e113-e116. doi: 10.1111/jdv.19464. Epub 2023 Aug 29. J Eur Acad Dermatol Venereol. 2024. PMID: 37611277 No abstract available.
Risankizumab: Daily Practice Experience of High Need Patients.
Brunasso AMG, Burlando M, Amoruso F, Arancio L, Malara G, Manzo R, Montesu MA, Caldarola G. Brunasso AMG, et al. Biomedicines. 2023 Jun 20;11(6):1769. doi: 10.3390/biomedicines11061769. Biomedicines. 2023. PMID: 37371864 Free PMC article.